MA31162B1 - Préparation pharmaceutique pour soulager l'endométriose - Google Patents
Préparation pharmaceutique pour soulager l'endométrioseInfo
- Publication number
- MA31162B1 MA31162B1 MA32138A MA32138A MA31162B1 MA 31162 B1 MA31162 B1 MA 31162B1 MA 32138 A MA32138 A MA 32138A MA 32138 A MA32138 A MA 32138A MA 31162 B1 MA31162 B1 MA 31162B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical composition
- bone density
- dilution
- endometriosis
- uterine lining
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une composition pharmaceutique conçue pour traiter une endométriose sans réduire la densité osseuse. Cette composition contient un gestagène anti-androgène, de préférence 17a-cyanométhyl-17-ß-hydroxyestra-4,9-dièn-3one (dienogest), acétate de cyprotérone ou acétate de chlormadinone, dans une dose journalière qui est au maximum deux fois supérieure à la dose d'inhibition d'ovulation, avec un ou plusieurs adjuvants/supports pharmaceutiquement acceptables. La composition pharmaceutique selon cette invention permet de traiter une endométriose sans influencer négativement le métabolisme osseux, ni la densité osseuse, et permet en même temps de maintenir à un niveau acceptable les effets secondaires connus (par ex. Bouffées de chaleur, acné, influence négative sur le profil lipidique) engendrés par les médicaments classiques. Ladite composition pharmaceutique est par conséquent adaptée à une application à long terme.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07004202A EP1977752A1 (fr) | 2007-03-01 | 2007-03-01 | Composition pharmaceutique destinée à réduire l'endométriose |
PCT/EP2008/001451 WO2008104342A1 (fr) | 2007-03-01 | 2008-02-23 | Préparation pharmaceutique conçue pour traiter une endométriose |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31162B1 true MA31162B1 (fr) | 2010-02-01 |
Family
ID=38045772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32138A MA31162B1 (fr) | 2007-03-01 | 2009-08-04 | Préparation pharmaceutique pour soulager l'endométriose |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP1977752A1 (fr) |
JP (1) | JP2010520159A (fr) |
KR (1) | KR20090119829A (fr) |
CN (1) | CN101583364A (fr) |
AU (1) | AU2008221012A1 (fr) |
BR (1) | BRPI0806598A2 (fr) |
CA (1) | CA2673936A1 (fr) |
CO (1) | CO6190606A2 (fr) |
CR (1) | CR10912A (fr) |
DO (1) | DOP2009000171A (fr) |
EA (1) | EA200900829A1 (fr) |
EC (1) | ECSP099482A (fr) |
MA (1) | MA31162B1 (fr) |
MX (1) | MX2009007259A (fr) |
NZ (1) | NZ577761A (fr) |
SV (1) | SV2009003324A (fr) |
TN (1) | TN2009000263A1 (fr) |
WO (1) | WO2008104342A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101874806A (zh) * | 2009-04-29 | 2010-11-03 | 北京本草天源药物研究院 | 一种地诺孕素固体制剂 |
CN102670519B (zh) * | 2011-03-16 | 2014-06-11 | 重庆莱美药业股份有限公司 | 一种可快速溶出的地诺孕素口服制剂及其制备方法 |
CN103304619B (zh) * | 2013-06-08 | 2015-12-02 | 西藏海思科药业集团股份有限公司 | 一种地诺孕素化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
EP1535618A1 (fr) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine |
MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
DE102004026679A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
EP1655031A1 (fr) * | 2004-10-08 | 2006-05-10 | Schering AG | Utilisation de dienogest pour contraceptives hormonelles avec cycle prolongué |
-
2007
- 2007-03-01 EP EP07004202A patent/EP1977752A1/fr not_active Withdrawn
-
2008
- 2008-02-23 NZ NZ577761A patent/NZ577761A/en not_active IP Right Cessation
- 2008-02-23 AU AU2008221012A patent/AU2008221012A1/en not_active Abandoned
- 2008-02-23 EA EA200900829A patent/EA200900829A1/ru unknown
- 2008-02-23 KR KR1020097014169A patent/KR20090119829A/ko not_active Application Discontinuation
- 2008-02-23 BR BRPI0806598-5A patent/BRPI0806598A2/pt not_active IP Right Cessation
- 2008-02-23 JP JP2009551120A patent/JP2010520159A/ja active Pending
- 2008-02-23 EP EP08707797A patent/EP2059248A1/fr not_active Ceased
- 2008-02-23 CN CNA2008800023330A patent/CN101583364A/zh active Pending
- 2008-02-23 CA CA002673936A patent/CA2673936A1/fr not_active Abandoned
- 2008-02-23 WO PCT/EP2008/001451 patent/WO2008104342A1/fr active Application Filing
- 2008-02-23 MX MX2009007259A patent/MX2009007259A/es unknown
-
2009
- 2009-06-24 TN TNP2009000263A patent/TN2009000263A1/fr unknown
- 2009-07-03 SV SV2009003324A patent/SV2009003324A/es not_active Application Discontinuation
- 2009-07-03 CO CO09068629A patent/CO6190606A2/es not_active Application Discontinuation
- 2009-07-03 CR CR10912A patent/CR10912A/es unknown
- 2009-07-03 EC EC2009009482A patent/ECSP099482A/es unknown
- 2009-07-03 DO DO2009000171A patent/DOP2009000171A/es unknown
- 2009-08-04 MA MA32138A patent/MA31162B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2059248A1 (fr) | 2009-05-20 |
NZ577761A (en) | 2012-03-30 |
ECSP099482A (es) | 2009-08-28 |
AU2008221012A1 (en) | 2008-09-04 |
CA2673936A1 (fr) | 2008-09-04 |
TN2009000263A1 (en) | 2010-10-18 |
EP1977752A1 (fr) | 2008-10-08 |
CN101583364A (zh) | 2009-11-18 |
DOP2009000171A (es) | 2009-08-31 |
CR10912A (es) | 2009-08-13 |
JP2010520159A (ja) | 2010-06-10 |
CO6190606A2 (es) | 2010-08-19 |
SV2009003324A (es) | 2009-10-02 |
MX2009007259A (es) | 2009-07-10 |
WO2008104342A1 (fr) | 2008-09-04 |
EA200900829A1 (ru) | 2010-02-26 |
KR20090119829A (ko) | 2009-11-20 |
BRPI0806598A2 (pt) | 2014-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schattenberg et al. | A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA | |
Kim et al. | Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function | |
Zelander | Ultrastructure of the mouse adrenal cortex: an electron microscopical study in intact and hydrocortisone-treated male adults | |
Tipoe et al. | Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice | |
FI3140393T3 (fi) | Menetelmä aikuisen maksan esisolujen tuottamiseksi | |
Docherty et al. | The role of sex in the pathophysiology of pulmonary hypertension | |
MA31162B1 (fr) | Préparation pharmaceutique pour soulager l'endométriose | |
Suyavaran et al. | TNF-α suppression by glutathione preconditioning attenuates hepatic ischemia reperfusion injury in young and aged rats | |
Kim et al. | Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma | |
Jirouskova et al. | Plectin controls biliary tree architecture and stability in cholestasis | |
Zhang et al. | A new approach for Alzheimer's disease treatment through P-gp regulation via ibuprofen | |
van Golen et al. | The pathophysiology of human obstructive cholestasis is mimicked in cholestatic Gold Syrian hamsters | |
Loughlin | Calcium channel blockers and prostate cancer | |
Cardoso et al. | The P2Y1 receptor-mediated leukocyte adhesion to endothelial cells is inhibited by melatonin | |
Gomez-Lechon et al. | The immunosuppressant drug FK506 prevents Fas-induced apoptosis in human hepatocytes | |
Wong et al. | Post exposure administration of A1 adenosine receptor agonists attenuates noise-induced hearing loss | |
Parés | Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? | |
Kim et al. | Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines | |
Jensen et al. | Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia | |
Russell et al. | Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there? | |
Ozdil et al. | New therapeutic option with N-acetylcysteine for primary sclerosing cholangitis: two case reports | |
Ceresa et al. | Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells | |
Mathurin et al. | Treatment of severe forms of alcoholic hepatitis: where are we going? | |
Singh et al. | Sanguinarine downregulates AT1a gene expression in a hypertensive rat model | |
Agarwal et al. | Can subepididymal orchiectomy Re-emerge as the treatment of choice in patients with advanced prostatic carcinoma? |